ActoGeniX is trying to tap into the industry's biologicals craze with a gut-centric delivery system that uses genetically modified bacteria to produce and deliver drugs. The company will develop its ActoBiotics for the treatment of severe gastrointestinal diseases, metabolic diseases, immune disorders, and allergies, where it feels that there is either an unmet need or its therapeutics can offer a significant advantage over existing products.
Technologiepark 4
9052 Zwijnaarde
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
